Premium
Single‐dose inhaled budesonide in subjects with chronic asthma
Author(s) -
Engel T.,
Dirksen A.,
Heinig J. H.,
Nielsen N. H.,
Weeke B.,
Johansson S. Å.
Publication year - 1991
Publication title -
allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.363
H-Index - 173
eISSN - 1398-9995
pISSN - 0105-4538
DOI - 10.1111/j.1398-9995.1991.tb00619.x
Subject(s) - budesonide , medicine , asthma , placebo , pulmonary function testing , inhalation , anesthesia , alternative medicine , pathology
In 30 stable asthmatics, a comparison was made between the changes in pulmonary function (FEV 1 , FVC, PEF, MEF 75 , MEF 50 and MEF 25 ) hourly for 9 h after a single dose of inhaled budesonide 1,600 μg, and placebo. All subjects used inhaled steroids daily; this medication was, however, withheld 8 days prior to the study. For all parameters of pulmonary function, a significant difference in favour of budesonide was demonstrated. The effect tended to decrease after 9 h, and had abated within 24 h. FEV 1 age, sex, smoking habits, or results of an inhaled β 2 ‐agonist reversibility test could not be demonstrated as predictors of those subjects to react with the most pronounced responses to budesonide. In conclusion, our results demonstrate an effect 3 h after administration of an inhaled glucocorticosteroid in adult outpatients with chronic asthma. These results parallel previous findings in highly selected asthmatics and after systemic administration of glucocorticosteroids. Single‐dose administration and subsequent monitoring for 8‐9 h may therefore prove valuable in evaluating new prophylactic agents for the treatment of asthma.